Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
| Ticker |
Sentiment |
Impact |
|
AZN
|
Neutral
|
24 %
|
|
BVS
|
Somewhat Bullish
|
35 %
|
|
FULC
|
Somewhat Bullish
|
30 %
|
